8-K: INVO Bioscience Faces Nasdaq Delisting Notice After Failing to Meet Equity Requirements

INVO Bioscience received a delisting notice from Nasdaq after failing to maintain the required minimum stockholders' equity, while also assigning a lease for a Tampa clinic for $475,000.

Summary

• INVO Bioscience's subsidiary, INVO Centers LLC, assigned its lease for a Tampa clinic to Brown Fertility Associates for $475,000.
• The company used $356,546.66 of the proceeds to pay for the buildout and accrued rent of the premises.
• The remaining funds from the lease assignment will be used for general working capital.
• INVO Bioscience received a notice from Nasdaq stating that it no longer complies with the minimum stockholders' equity requirement of $2,500,000.
• The company's stockholders' equity was reported as $892,825 as of December 31, 2023.
• A previous Nasdaq Hearings Panel had confirmed the company's compliance, but imposed a monitoring period until November 22, 2024.
• The delisting notice has no immediate effect, and the company's stock continues to trade on Nasdaq.
• INVO Bioscience intends to appeal the delisting determination by April 24, 2024.
• The company is evaluating options to regain compliance with Nasdaq's equity rule.

Sentiment

Score: 3

Explanation: The document contains significant negative news regarding a delisting notice, which overshadows the positive aspect of the lease assignment. The company's future is uncertain.

Positives

• The assignment of the Tampa clinic lease generated $475,000 in proceeds.
• The company was fully released from its lease obligations by the Landlord.
• The remaining proceeds from the lease assignment will be used for general working capital.

Negatives

• The company received a delisting notice from Nasdaq due to insufficient stockholders' equity.
• The company's stockholders' equity of $892,825 is significantly below the required $2,500,000.
• There is no assurance that the company's plan to regain compliance will be accepted by Nasdaq.
• The company may be delisted if it fails to regain compliance or satisfy other Nasdaq requirements.

Risks

• The company faces the risk of being delisted from Nasdaq if it cannot regain compliance with the minimum stockholders' equity requirement.
• There is no guarantee that the company's appeal or plan to regain compliance will be accepted by Nasdaq.
• Failure to regain compliance could negatively impact the company's stock price and investor confidence.
• The company's focus on acquiring profitable fertility clinics may be impacted by the delisting risk.

Future Outlook

The company intends to appeal the delisting notice and is evaluating various courses of action to regain compliance with Nasdaq's equity rule, but there is no assurance of success.

Management Comments

• The company opted to assign the lease due to the unavailability of the doctor for the proposed Tampa INVO Center and its focus on acquiring profitable fertility clinics.
• The company plans to timely submit its plan to the Panel to regain compliance with the Equity Rule.

Industry Context

The fertility clinic industry is competitive, and INVO Bioscience's focus on acquiring profitable clinics is a common strategy. However, the delisting notice adds significant uncertainty to the company's future.

Comparison to Industry Standards

• Many small-cap biotech companies struggle to maintain Nasdaq listing requirements, particularly those in the early stages of commercialization.
• Companies like INVO Bioscience often face challenges in achieving profitability and maintaining sufficient equity, which can lead to delisting risks.
• Other companies in the fertility space, such as CooperSurgical and Boston IVF, are larger and more established, with stronger financial positions.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment value.
• Employees may experience uncertainty regarding the company's future.
• Customers may be concerned about the company's ability to continue operations.
• Creditors may be concerned about the company's financial stability.

Next Steps

• The company will appeal the delisting determination by April 24, 2024.
• The company will submit a plan to Nasdaq to regain compliance with the equity rule.
• The company will continue to evaluate options to regain compliance.

Key Dates

Keywords

delisting, Nasdaq, stockholders' equity, lease assignment, INVO Bioscience, compliance, fertility clinics, working capital